A Phase I/II multicenter study of IY5511HCI in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/or Dasatinib, Nilotinib).

Trial Profile

A Phase I/II multicenter study of IY5511HCI in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/or Dasatinib, Nilotinib).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Radotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Il-Yang
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 23 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 04 Mar 2014 Planned end date changed from 1 Jul 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top